SELLAS Life Sciences Group (SLS) Financials

SELLAS Life Sciences Group logo
$7.47 -0.39 (-4.96%)
Closing price 04:00 PM Eastern
Extended Trading
$7.95 +0.48 (+6.43%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for SELLAS Life Sciences Group

Annual Income Statements for SELLAS Life Sciences Group

This table shows SELLAS Life Sciences Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-64 -18 -24 -41 -28 -17 -21 -41 -37 -31 -27
Consolidated Net Income / (Loss)
-64 -18 -24 -28 -19 -17 -21 -41 -37 -31 -27
Net Income / (Loss) Continuing Operations
-39 -18 -24 -28 -19 -17 -21 -41 -37 -31 -27
Total Pre-Tax Income
-39 -18 -24 -29 -19 -17 -21 -41 -37 -31 -27
Total Operating Income
-34 -16 -23 -31 -20 -17 -25 -42 -38 -32 -28
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 1.90 7.40 0.90 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 1.90 7.60 1.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.10 0.00 0.00 0.00
Total Operating Expenses
34 16 23 31 20 19 33 43 38 32 28
Selling, General & Admin Expense
11 4.59 15 13 9.92 9.60 11 13 14 12 12
Research & Development Expense
24 11 6.07 8.77 7.29 9.28 16 30 24 19 16
Total Other Income / (Expense), net
-4.37 -1.69 -0.46 2.04 0.67 0.21 4.36 0.65 0.53 0.63 1.41
Interest & Investment Income
-0.76 - - - - - - - 0.53 0.63 1.41
Basic Earnings per Share
($8.23) ($18.66) ($10.44) ($157.72) ($10.92) ($2.11) ($1.34) ($2.13) ($1.34) ($0.50) ($0.25)
Weighted Average Basic Shares Outstanding
7.76M 947.40K 2.34M 261.54K 2.56M 7.98M 15.48M 19.40M 27.78M 61.20M 109.05M
Diluted Earnings per Share
($8.23) ($18.66) ($10.44) ($157.72) ($10.92) ($2.11) ($1.34) ($2.13) ($1.34) ($0.50) ($0.25)
Weighted Average Diluted Shares Outstanding
7.76M 947.40K 2.34M 261.54K 2.56M 7.98M 15.48M 19.40M 27.78M 61.20M 109.05M
Weighted Average Basic & Diluted Shares Outstanding
7.76M 947.40K 2.34M 261.54K 2.56M 7.98M 15.91M 28.30M 56.27M 90.85M 179.58M

Quarterly Income Statements for SELLAS Life Sciences Group

This table shows SELLAS Life Sciences Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 7.08 - - - 11
Net Income / (Loss) Attributable to Common Shareholders
-9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41 -9.61 -10
Consolidated Net Income / (Loss)
-9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41 -9.61 -10
Net Income / (Loss) Continuing Operations
-9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41 -9.61 -10
Total Pre-Tax Income
-9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41 -9.61 -10
Total Operating Income
-9.65 -7.62 -7.33 -6.92 -6.06 -6.87 -7.08 -8.26 -9.25 -11 -11
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
9.65 7.62 7.33 6.92 6.06 6.87 7.08 8.26 9.25 11 11
Selling, General & Admin Expense
4.53 2.44 2.97 2.48 2.86 3.00 2.87 3.53 4.12 4.36 4.28
Research & Development Expense
5.11 5.19 4.36 4.44 3.21 3.87 4.22 4.73 5.13 6.27 7.03
Total Other Income / (Expense), net
0.08 0.15 0.22 0.18 0.25 0.27 0.29 0.60 0.85 1.02 1.22
Interest & Investment Income
0.08 0.15 0.22 - 0.25 0.27 0.29 0.60 0.85 1.02 1.22
Basic Earnings per Share
($0.21) ($0.13) ($0.10) ($0.06) ($0.07) ($0.07) ($0.06) ($0.05) ($0.05) ($0.05) ($0.05)
Weighted Average Basic Shares Outstanding
44.81M 57.63M 68.25M 61.20M 87.76M 98.56M 108.40M 109.05M 172.48M 189.18M 202.44M
Diluted Earnings per Share
($0.21) ($0.13) ($0.10) ($0.06) ($0.07) ($0.07) ($0.06) ($0.05) ($0.05) ($0.05) ($0.05)
Weighted Average Diluted Shares Outstanding
44.81M 57.63M 68.25M 61.20M 87.76M 98.56M 108.40M 109.05M 172.48M 189.18M 202.44M
Weighted Average Basic & Diluted Shares Outstanding
57.75M 64.33M 70.38M 90.85M 99.78M 105.30M 142.44M 179.58M 186.03M 201.95M 203.86M

Annual Cash Flow Statements for SELLAS Life Sciences Group

This table details how cash moves in and out of SELLAS Life Sciences Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
6.08 4.57 6.70 -7.30 1.93 28 -14 -4.23 -15 11 58
Net Cash From Operating Activities
-48 -12 -11 -30 -18 -10 -26 -24 -31 -35 -28
Net Cash From Continuing Operating Activities
-39 -12 -11 -30 -18 -10 -26 -24 -31 -35 -28
Net Income / (Loss) Continuing Operations
-64 -18 -24 -28 -19 -17 -21 -41 -37 -31 -27
Consolidated Net Income / (Loss)
-39 -18 -24 -28 -19 -17 -21 -41 -37 -31 -27
Amortization Expense
-0.25 - 0.26 - 0.00 - - - - 0.56 0.60
Non-Cash Adjustments To Reconcile Net Income
32 4.52 6.46 8.57 2.86 0.77 3.48 11 2.04 1.56 1.96
Changes in Operating Assets and Liabilities, net
15 1.31 6.07 -11 -1.21 5.57 -8.80 6.11 3.86 -6.65 -4.08
Net Cash From Investing Activities
10 -0.09 12 0.00 0.00 0.00 0.00 -4.50 -5.50 0.00 0.00
Net Cash From Continuing Investing Activities
-0.35 -0.09 12 0.00 0.00 0.00 0.00 -4.50 -5.50 0.00 0.00
Net Cash From Financing Activities
44 17 5.53 23 20 38 12 24 22 47 86
Net Cash From Continuing Financing Activities
44 17 5.53 23 20 38 12 24 22 47 86
Issuance of Common Equity
48 - 6.01 22 16 30 9.01 24 22 46 74
Other Financing Activities, net
0.03 - - 0.00 3.60 8.84 3.07 0.00 -0.02 0.50 12
Cash Interest Received
0.02 - 0.00 0.19 0.12 0.03 0.01 0.32 0.53 0.63 1.41

Quarterly Cash Flow Statements for SELLAS Life Sciences Group

This table details how cash moves in and out of SELLAS Life Sciences Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
16 -9.27 12 -7.15 15 -3.10 19 27 35 31 -3.63
Net Cash From Operating Activities
-11 -9.68 -7.81 -7.15 -9.07 -7.33 -7.07 -4.92 -8.85 -7.59 -5.94
Net Cash From Continuing Operating Activities
-11 -9.68 -7.81 -7.22 -9.07 -7.33 -7.07 -4.92 -8.85 -7.59 -5.94
Net Income / (Loss) Continuing Operations
-9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41 -9.61 -10
Consolidated Net Income / (Loss)
-9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41 -9.61 -10
Amortization Expense
0.14 - - 0.15 0.15 - - 0.15 0.15 0.15 0.15
Non-Cash Adjustments To Reconcile Net Income
0.48 0.61 0.11 0.17 0.51 0.80 0.21 0.45 0.80 1.02 1.46
Changes in Operating Assets and Liabilities, net
-1.81 -2.68 -1.22 -0.80 -3.91 -1.38 -0.93 2.14 -1.39 0.85 2.54
Net Cash From Financing Activities
27 0.41 20 0.01 24 4.23 26 32 44 39 2.31
Net Cash From Continuing Financing Activities
27 0.41 20 0.01 24 4.23 26 32 44 39 2.31
Issuance of Common Equity
27 0.06 20 0.07 23 0.02 22 29 0.07 - 0.08
Other Financing Activities, net
0.05 0.36 0.16 -0.06 0.50 4.21 4.00 3.38 44 39 2.22
Cash Interest Received
0.08 0.15 0.22 0.18 0.25 0.27 0.29 0.60 0.85 1.02 1.22

Annual Balance Sheets for SELLAS Life Sciences Group

This table presents SELLAS Life Sciences Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
82 6.42 34 17 17 46 26 21 6.22 19 78
Total Current Assets
54 6.38 13 5.84 8.24 37 23 18 3.17 16 75
Cash & Equivalents
30 5.96 2.32 5.34 7.28 35 21 17 2.53 14 72
Restricted Cash
0.40 0.09 10 0.11 0.10 0.10 0.10 0.10 0.10 0.10 0.10
Prepaid Expenses
1.40 0.33 0.34 0.39 0.56 0.40 1.59 0.53 0.54 2.34 3.32
Plant, Property, & Equipment, net
0.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
28 0.04 20 11 8.37 9.12 3.23 3.19 3.05 3.11 3.13
Goodwill
5.90 - 1.91 1.91 1.91 1.91 1.91 1.91 1.91 1.91 1.91
Other Noncurrent Operating Assets
22 0.04 19 9.16 6.45 7.21 1.32 1.27 1.13 1.19 1.22
Total Liabilities & Shareholders' Equity
82 6.42 34 17 17 46 26 21 6.22 19 78
Total Liabilities
69 11 31 12 11 18 5.93 16 14 9.97 7.47
Total Current Liabilities
57 5.76 25 5.97 5.29 12 4.98 16 14 9.51 7.02
Accounts Payable
1.60 - 12 3.76 3.90 4.66 2.14 3.36 5.64 3.50 2.95
Accrued Expenses
5.29 4.05 3.20 2.22 1.17 1.91 2.64 6.29 7.65 5.47 3.53
Other Current Liabilities
40 - 1.30 - 0.22 0.22 0.20 5.87 0.45 0.54 0.54
Total Noncurrent Liabilities
12 5.66 6.89 5.70 5.23 5.70 0.95 0.58 0.46 0.46 0.46
Other Noncurrent Operating Liabilities
6.14 - 2.60 5.34 4.96 5.46 0.95 0.58 0.46 0.46 0.46
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
14 -5.00 2.07 5.25 6.09 28 20 4.85 -7.98 9.47 71
Total Preferred & Common Equity
14 -5.00 2.07 5.25 6.09 28 20 4.85 -7.98 9.47 71
Total Common Equity
14 -5.00 2.07 5.25 6.09 28 20 4.85 -7.98 9.47 71
Common Stock
297 25 56 87 107 146 159 185 209 258 346
Retained Earnings
- -30 -54 -82 -101 -118 -139 -180 -217 -248 -275

Quarterly Balance Sheets for SELLAS Life Sciences Group

This table presents SELLAS Life Sciences Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
19 8.09 24 15 27 35 32 52 114 145 141
Total Current Assets
16 5.20 22 12 24 32 29 49 111 143 139
Cash & Equivalents
14 3.97 18 9.15 21 28 25 44 107 138 135
Restricted Cash
0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
Prepaid Expenses
1.67 1.13 2.99 3.06 2.90 3.48 4.05 4.63 3.97 4.06 3.76
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
2.99 2.88 2.93 2.82 2.47 2.98 2.86 2.50 3.01 2.88 2.52
Goodwill
1.91 1.91 1.91 1.91 1.91 1.91 1.91 1.91 1.91 1.91 1.91
Other Noncurrent Operating Assets
1.07 0.97 1.02 0.90 0.56 1.07 0.94 0.59 1.09 0.96 0.60
Total Liabilities & Shareholders' Equity
19 8.09 24 15 27 35 32 52 114 145 141
Total Liabilities
14 12 15 12 11 7.20 6.16 5.93 6.77 7.73 9.29
Total Current Liabilities
13 12 14 12 11 6.89 6.00 5.93 6.46 7.57 9.29
Accounts Payable
3.73 4.34 7.41 6.33 4.55 3.76 3.34 2.31 3.63 3.09 2.09
Accrued Expenses
6.24 6.93 6.54 5.18 5.49 2.57 2.08 3.02 2.26 3.90 6.60
Other Current Liabilities
3.45 0.47 0.49 0.53 0.58 0.56 0.58 0.60 0.56 0.58 0.60
Total Noncurrent Liabilities
0.30 0.18 0.31 0.16 0.00 0.31 0.16 0.00 0.31 0.16 0.00
Other Noncurrent Operating Liabilities
0.30 0.18 0.31 0.16 0.00 0.31 0.16 0.00 0.31 0.16 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
4.84 -3.83 9.68 2.91 16 28 26 46 107 138 132
Total Preferred & Common Equity
4.84 -3.83 9.68 2.91 16 28 26 46 107 138 132
Total Common Equity
4.84 -3.83 9.68 2.91 16 28 26 46 107 138 132
Common Stock
205 205 236 237 257 282 287 313 391 431 435
Retained Earnings
-200 -209 -227 -234 -241 -254 -261 -267 -283 -293 -303

Annual Metrics And Ratios for SELLAS Life Sciences Group

This table displays calculated financial ratios and metrics derived from SELLAS Life Sciences Group's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
161,906,753.00 217,019,065.00 45,712,912.00 22,026,476.00 4,871,927.00 9,461,978.00 15,885,542.00 20,588,247.00 32,062,258.00 - 142,442,239.00
DEI Adjusted Shares Outstanding
5,397.00 7,234.00 30,475.00 440,530.00 4,871,927.00 9,461,978.00 15,885,542.00 20,588,247.00 32,062,258.00 - 142,442,239.00
DEI Earnings Per Adjusted Shares Outstanding
-11,840.28 -2,444.15 -801.61 -93.64 -5.74 -1.78 -1.30 -2.01 -1.16 - -0.19
Growth Metrics
- - - - - - - - - - -
Profitability Metrics
- - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)
-24 -11 -16 -22 -14 -12 -18 -29 -27 -22 -20
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 332.35% -233.06% -27.93%
Earnings before Interest and Taxes (EBIT)
-38 -17 -23 -30 -19 -17 -21 -42 -38 -32 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-38 -17 -23 -30 -19 -17 -21 -42 -38 -31 -28
Valuation Ratios
- - - - - - - - - - -
Leverage & Solvency
- - - - - - - - - - -
Liquidity Ratios
- - - - - - - - - - -
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-16 -14 -20 -21 -13 -5.73 -24 -18 -28 -28 -23
Efficiency Ratios
- - - - - - - - - - -
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-6.35 -3.68 0.31 -0.21 -1.28 -7.44 -1.11 -12 -11 -4.52 -1.02
Increase / (Decrease) in Invested Capital
-8.11 2.67 3.98 -0.51 -1.08 -6.16 6.33 -11 1.77 6.09 3.50
Book Value per Share
$0.08 ($0.02) $0.05 $0.24 $1.25 $2.96 $1.28 $0.24 ($0.25) $0.13 $0.50
Tangible Book Value per Share
$0.05 ($0.02) $0.00 $0.15 $0.86 $2.75 $1.16 $0.14 ($0.31) $0.11 $0.48
Total Capital
18 2.37 13 5.25 6.09 28 20 4.85 -7.98 9.47 71
Total Debt
4.74 7.37 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 5.66 2.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-25 1.32 -1.76 -5.45 -7.38 -35 -21 -17 -2.63 -14 -72
Capital Expenditures (CapEx)
-12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-29 -3.72 -16 -5.59 -4.43 -11 -3.39 -15 -13 -7.17 -3.70
Debt-free Net Working Capital (DFNWC)
1.29 2.33 -3.11 -0.14 2.95 25 18 2.24 -11 6.82 68
Net Working Capital (NWC)
-3.45 0.62 -11 -0.14 2.95 25 18 2.24 -11 6.82 68
Net Nonoperating Expense (NNE)
40 6.49 7.63 5.91 5.26 4.87 2.99 12 11 8.82 7.07
Net Nonoperating Obligations (NNO)
-20 1.32 -1.76 -5.45 -7.38 -35 -21 -17 -2.63 -14 -72
Total Depreciation and Amortization (D&A)
-0.14 0.00 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.56 0.60
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($12,300.01) ($3,540.00) ($522.00) ($157.50) ($10.92) ($2.11) ($1.34) ($2.13) ($1.34) ($0.50) ($0.25)
Adjusted Weighted Average Basic Shares Outstanding
6.06K 25.89K 46.81K 463.53K 6.72M 15.08M 15.48M 19.40M 27.78M 61.20M 109.05M
Adjusted Diluted Earnings per Share
($12,300.01) ($3,540.00) ($522.00) ($157.50) ($10.92) ($2.11) ($1.34) ($2.13) ($1.34) ($0.50) ($0.25)
Adjusted Weighted Average Diluted Shares Outstanding
6.06K 25.89K 46.81K 463.53K 6.72M 15.08M 15.48M 19.40M 27.78M 61.20M 109.05M
Adjusted Basic & Diluted Earnings per Share
($12,300.01) ($3,540.00) ($522.00) ($157.50) ($10.92) ($2.11) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
5.18K 6.64K 46.81K 261.54K 2.56M 7.98M 15.91M 28.30M 56.27M 90.85M 179.58M
Normalized Net Operating Profit after Tax (NOPAT)
-24 -11 -16 -15 -12 -12 -14 -29 -27 -22 -20
Debt Service Ratios
- - - - - - - - - - -
Payout Ratios
- - - - - - - - - - -

Quarterly Metrics And Ratios for SELLAS Life Sciences Group

This table displays calculated financial ratios and metrics derived from SELLAS Life Sciences Group's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
56,267,670.00 57,754,928.00 64,332,498.00 - 90,846,692.00 99,777,487.00 105,297,469.00 142,442,239.00 179,582,574.00 186,032,574.00 201,945,709.00
DEI Adjusted Shares Outstanding
56,267,670.00 57,754,928.00 64,332,498.00 - 90,846,692.00 99,777,487.00 105,297,469.00 142,442,239.00 179,582,574.00 186,032,574.00 201,945,709.00
DEI Earnings Per Adjusted Shares Outstanding
-0.17 -0.13 -0.11 - -0.06 -0.07 -0.06 -0.05 -0.05 -0.05 -0.05
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Growth
15.06% 14.27% 20.67% 17.21% 37.77% 9.82% 3.36% - -53.80% -55.79% -60.86%
EBIT Growth
14.49% 15.77% 21.71% 15.40% 37.14% 9.82% 3.36% - -52.60% -54.65% -59.66%
NOPAT Growth
14.50% 15.79% 21.71% 15.40% 37.14% 9.82% 3.36% - -52.60% -54.65% -59.66%
Net Income Growth
13.80% 15.50% 23.30% 17.20% 39.23% 11.63% 4.46% - -44.62% -45.51% -48.59%
EPS Growth
55.32% 58.06% 69.70% 73.91% 66.67% 46.15% 40.00% - 28.57% 28.57% 16.67%
Operating Cash Flow Growth
11.26% -27.97% -13.26% -48.25% 15.71% 24.29% 9.45% - 2.47% -3.52% 15.96%
Free Cash Flow Firm Growth
-18.44% -52.14% -3.72% -45.86% -40.94% -47.52% -46.48% - 39.78% 50.40% 67.56%
Invested Capital Growth
18.48% 30.12% 33.65% 57.37% 91.64% 111.87% 123.10% - 129.13% -204.65% -348.43%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-16.27% 19.84% 3.83% 5.87% 12.61% -16.18% -3.06% - -12.32% -15.12% -6.51%
EBIT Q/Q Growth
-17.95% 20.99% 3.83% 5.61% 12.36% -13.36% -3.06% - -12.08% -14.88% -6.40%
NOPAT Q/Q Growth
-17.95% 20.99% 3.83% 5.61% 12.36% -13.36% -3.06% - -12.08% -14.88% -6.40%
Net Income Q/Q Growth
-17.58% 21.91% 4.85% 5.22% 13.72% -13.56% -2.88% - -9.78% -14.25% -5.06%
EPS Q/Q Growth
8.70% 38.10% 23.08% 40.00% -16.67% 0.00% 14.29% - 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-123.03% 10.03% 19.38% 8.37% -26.80% 19.18% 3.57% - -79.76% 14.22% 21.72%
Free Cash Flow Firm Q/Q Growth
-16.84% 7.87% 3.44% -40.33% -12.90% 3.57% 4.12% - 19.92% 20.57% 37.30%
Invested Capital Q/Q Growth
16.74% 28.28% 17.29% 13.70% 83.68% 201.90% 60.90% - 121.04% -466.05% -281.96%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Interest Burden Percent
99.18% 98.02% 96.98% 97.38% 95.88% 96.04% 95.88% - 90.87% 90.37% 89.23%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
-313.39% -888.06% -535.10% -4,147.88% -144.90% -180.71% -84.33% - -43.58% -39.63% -40.31%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -3,472.62% -2,091.31% - -10,687.02% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-313.39% -888.06% -535.10% -4,147.88% -144.90% -180.71% -84.33% - -43.58% -39.63% -40.31%
Return on Equity Simple (ROE_SIMPLE)
-369.77% 0.00% 0.00% 0.00% -97.73% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.75 -5.33 -5.13 -4.84 -4.24 -4.81 -4.96 -5.78 -6.48 -7.44 -7.92
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-13.24% -18.44% -15.70% -22.80% -6.67% -10.33% -5.59% - -2.85% -2.64% -2.43%
Return On Investment Capital (ROIC_SIMPLE)
-69.72% -183.13% -32.28% -51.16% -15.29% -18.40% -10.87% -8.15% -6.03% -5.41% -6.01%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-9.65 -7.62 -7.33 -6.92 -6.06 -6.87 -7.08 -8.26 -9.25 -11 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-9.51 -7.62 -7.33 -6.77 -5.92 -6.87 -7.08 -8.10 -9.10 -10 -11
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
5.87 23.59 5.06 7.73 3.53 8.36 3.72 - 7.07 19.95 18.86
Price to Tangible Book Value (P/TBV)
7.31 68.80 5.75 9.69 3.80 9.02 3.88 - 7.20 20.23 19.14
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 256.80 103.40 - 3,034.59 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Financial Leverage
-1.86 -2.99 -2.09 -11.16 -1.26 -1.19 -1.07 - -1.00 -1.00 -1.01
Leverage Ratio
2.34 4.34 2.87 17.23 1.59 1.63 1.27 - 1.10 1.08 1.09
Compound Leverage Factor
2.32 4.26 2.78 16.78 1.52 1.57 1.22 - 1.00 0.98 0.97
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Altman Z-Score
-11.64 -19.96 -8.51 -14.22 -1.70 10.18 10.46 - 64.73 211.29 158.45
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.49 1.02 2.26 1.72 4.64 4.91 8.28 - 17.22 18.83 14.92
Quick Ratio
1.28 0.76 1.98 1.46 4.12 4.22 7.48 - 16.59 18.28 14.51
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-8.75 -8.06 -7.79 -11 -12 -12 -11 -9.28 -7.43 -5.90 -3.70
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-8.83 -6.33 -5.24 -4.52 -0.74 0.75 1.21 -1.02 0.22 -0.79 -3.01
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
2.00 2.73 2.66 6.09 8.09 7.09 6.45 3.50 0.95 -1.54 -4.22
Enterprise Value (EV)
38 59 59 59 70 193 125 - 652 2,607 2,351
Market Capitalization
57 69 80 73 98 219 170 - 760 2,746 2,486
Book Value per Share
$0.17 $0.05 $0.25 $0.13 $0.31 $0.26 $0.43 $0.50 $0.60 $0.74 $0.65
Tangible Book Value per Share
$0.14 $0.02 $0.22 $0.11 $0.28 $0.24 $0.42 $0.48 $0.59 $0.73 $0.64
Total Capital
9.68 2.91 16 9.47 28 26 46 71 107 138 132
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-19 -9.25 -21 -14 -28 -25 -44 -72 -107 -138 -135
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-11 -8.99 -7.71 -7.17 -3.41 -1.95 -1.29 -3.70 -2.48 -3.51 -5.52
Debt-free Net Working Capital (DFNWC)
7.06 0.26 13 6.82 25 23 43 68 105 135 129
Net Working Capital (NWC)
7.06 0.26 13 6.82 25 23 43 68 105 135 129
Net Nonoperating Expense (NNE)
2.81 2.14 1.98 1.89 1.57 1.79 1.83 1.88 1.93 2.16 2.17
Net Nonoperating Obligations (NNO)
-19 -9.25 -21 -14 -28 -25 -44 -72 -107 -138 -135
Total Depreciation and Amortization (D&A)
0.14 0.00 0.00 0.15 0.15 0.00 0.00 0.15 0.15 0.15 0.15
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.21) ($0.13) ($0.10) ($0.06) ($0.07) ($0.07) ($0.06) ($0.05) ($0.05) ($0.05) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding
44.81M 57.63M 68.25M 61.20M 87.76M 98.56M 108.40M 109.05M 172.48M 189.18M 202.44M
Adjusted Diluted Earnings per Share
($0.21) ($0.13) ($0.10) ($0.06) ($0.07) ($0.07) ($0.06) ($0.05) ($0.05) ($0.05) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding
44.81M 57.63M 68.25M 61.20M 87.76M 98.56M 108.40M 109.05M 172.48M 189.18M 202.44M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
57.75M 64.33M 70.38M 90.85M 99.78M 105.30M 142.44M 179.58M 186.03M 201.95M 203.86M
Normalized Net Operating Profit after Tax (NOPAT)
-6.75 -5.33 -5.13 -4.84 -4.24 -4.81 -4.96 -5.78 -6.48 -7.44 -7.92
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

SELLAS Life Sciences Group’s Q2 2026 statements show a substantially stronger liquidity position, but the company remains dependent on financing while clinical development expenses continue to produce operating losses. Cash and equivalents increased to $138.3 million at June 30, 2026, from $107.1 million in Q1 2026 and $21.0 million in Q3 2024. The improvement was driven primarily by $38.8 million of net financing cash inflow, which more than offset the company’s $7.6 million operating cash burn.

The balance sheet is currently liquid, with $142.5 million of current assets compared with only $7.6 million of current liabilities. However, SELLAS reported no revenue in the periods provided, and its accumulated deficit reached $293.0 million. The company’s financial progress therefore remains closely tied to its pipeline, clinical outcomes and ability to access additional capital.

  • Cash reserves have expanded significantly: Cash and equivalents rose approximately 29% sequentially to $138.3 million in Q2 2026 and were more than six times the $21.0 million reported in Q3 2024.
  • Strong short-term liquidity: Current assets of $142.5 million compared with current liabilities of $7.6 million, indicating substantial coverage of near-term obligations and a current ratio of roughly 18.8.
  • Low balance-sheet leverage: Total liabilities were $7.7 million against $137.7 million of equity, and the company reported no significant debt balance in the provided statements.
  • Operating cash burn improved sequentially: Net cash used in operating activities declined to $7.6 million in Q2 2026 from $8.8 million in Q1 2026, although the improvement was modest relative to the company’s cash balance.
  • Interest income is becoming a useful offset: Interest and investment income increased to $1.0 million in Q2 2026 from $845,000 in Q1 2026 and $272,000 in Q2 2025, reflecting the benefit of holding larger cash reserves.
  • Financing has been the primary source of cash growth: SELLAS generated $38.8 million from financing in Q2 2026 and $44.2 million in Q1 2026, suggesting that recent liquidity improvement has come largely from capital raising rather than business operations.
  • Estimated cash runway appears extended but uncertain: Based on Q2 operating cash use of $7.6 million, the company has several years of cash coverage on a simple run-rate basis. Clinical trial expansion, milestone payments or higher research spending could materially change that estimate.
  • SELLAS remains unprofitable with no reported revenue: Revenue and gross profit were both zero in Q2 2026, while the company recorded a net loss of $9.6 million, or $0.05 per share.
  • Operating expenses are trending higher: Q2 2026 operating expenses rose to $10.6 million from $9.3 million in Q1 2026 and $6.9 million in Q2 2025. Research and development expense increased to $6.3 million, indicating heavier investment in development programs.
  • Losses and cash burn remain persistent: The company has reported operating cash outflows in each supplied quarter, while retained earnings declined to a deficit of $293.0 million by Q2 2026.
  • Shareholder dilution is a major risk: Weighted-average basic shares outstanding increased to 189.2 million in Q2 2026 from 98.6 million in Q2 2025 and 44.8 million in Q1 2024. Continued reliance on equity financing could reduce each existing shareholder’s ownership percentage.
11/16/26 11:10 PM ETAI Generated. May Contain Errors.

SELLAS Life Sciences Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, SELLAS Life Sciences Group's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

In the past 10 years, SELLAS Life Sciences Group's net income has ranged from -$63.90 million in 2015 to -$16.76 million in 2020, and is currently -$26.86 million as of their latest financial filing in 2025. Check out SELLAS Life Sciences Group's forecast to explore projected trends and price targets.

SELLAS Life Sciences Group's total operating income in 2025 was -$28.27 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $28.27 million

Over the last 10 years, SELLAS Life Sciences Group's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

In the past 13 quarters, SELLAS Life Sciences Group's cash and equivalents has ranged from $3.97 million in Q3 2023 to $138.34 million in Q2 2026, and is currently $134.71 million as of their latest financial filing in Q3 2026.

SELLAS Life Sciences Group had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2015.

Over the last 10 years, SELLAS Life Sciences Group's book value per share changed from 0.08 in 2015 to 0.50 in 2025, a change of 495.8%.



Financial statements for NASDAQ:SLS last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners